FDA Clears Ezra Prostate AI, a First for Cancer Imaging

FDA Clears Ezra Prostate AI, a First for Cancer Imaging
The U.S. Food and Drug Administration (FDA) has cleared Ezra Prostate AI, an artificial intelligence (AI) program designed to increase the efficiency with which radiologists analyze images of the prostate in order to diagnose prostate cancer. The program, which is expected to decrease the cost of prostate MRIs, is the first-ever prostate segmentation AI to be cleared by the FDA, Ezra announced in a press release. Despite the commonality of prostate cancer, there aren't reliable screening tests to detect the disease early, when treatments are generally more successful. The standard diagnosis approach involves measuring levels of the prostate-specific antigen (PSA) protein in the blood. But this method is very prone to false positives, so much so that it usually is not recommended for people with an average cancer risk. Imaging the prostate using MRI can detect clinically significant prostate cancers more effectively than PSA testing alone, which would decrease the need for unnecessary biopsies. However, MRIs are expensive; at a hospital, an MRI can cost as much as $4,000. Ezra previously developed a fast, 20-minute prostate cancer screening MRI, whic
Subscribe or to access all post and page content.